The researchers describe the different ways in which COVID-19 can cause serious inflammation-related cardiovascular problems.
They also provide guidance on how to deal with these problems.
Potential problems with drugs currently being administered to combat this virus are also highlighted.
A recent study by the Beijing Union Medical College & Chinese Academy of Medical Science concludes that cardiovascular anti-inflammatory therapies should be used to treat people with COVID-19 who suffer from cardiovascular problems or illnesses.
The results of the study were published in the English language journal “Frontiers in Cardiovascular Medicine”.
Proven anti-inflammatory therapies should be used in the treatment of COVID-19 patients who are at increased risk of cardiovascular problems or who have already developed these in the course of the disease.
How should people with severe COVID-19 be treated?
How should COVID-19 sufferers with cardiovascular problems be treated?
The research group was the first to extensively discuss the use of cardiovascular anti-inflammatory therapies for patients severely affected by COVID-19.
The study provides guidelines for the selection of specific cardiovascular anti-inflammatory therapies for people with COVID-19 that depend on the severity of the condition and the response of the affected person to the therapy.
In addition, the researchers point out the known risks of treatments for the cardiovascular system that are currently being tested on people with COVID-19.
The risk of pneumonia and shortness of breath in people with COVID-19 is already known, but there is increasing evidence of serious cardiovascular problems related to the disease.
Inflammation plays an important role in the development and complications of cardiovascular diseases.
The researchers observed that people with COVID-19 with stronger signs of an inflammatory reaction were more likely to experience severe cardiovascular events and were also at higher risk of death.
COVID-19 can cause inflammation-related cardiovascular problems
The study identified a number of ways in which COVID-19 could trigger cardiovascular problems.
The virus can directly infect the heart tissue and cause inflammation, exacerbate existing cardiovascular problems or trigger an exaggerated immune response in the body, the researchers report.
By investigating current promising treatments for COVID-19 and cardiovascular anti-inflammatory therapies, which have already been verified in clinical trials with positive results, the research group was able to highlight potentially effective treatments.
In such a case, you are advised to carry out anti-inflammatory treatment to support recovery.
Important NOTE:
This article contains general information only and should not be used for self-diagnosis or treatment.
He can not substitute a visit at the doctor.
Some drugs, such as lopinavir / ritonavir, interferon-α, ribavirin, azithromycin, and hydroxychloroquine, that are currently used to treat COVID-19 can actually increase the risk of cardiovascular impairment, the research group explains.
Given that these drugs, particularly the antiviral agents, can be essential in the clinical treatment of people with COVID-19, cardiovascular protection strategies are urgently needed to improve the overall prognosis.
(as)
However, the researchers warn against the use of new, pre-clinical drugs for the treatment of COVID-19 because of their unknown effectiveness and safety risks.
In addition, caution should be exercised when using certain antiviral drugs, some of which are currently being clinically tested for the treatment of COVID-19.
Tekk.tv health
–
